+Search query
-Structure paper
Title | The Myxobacterial Antibiotic Myxovalargin: Biosynthesis, Structural Revision, Total Synthesis, and Molecular Characterization of Ribosomal Inhibition. |
---|---|
Journal, issue, pages | J Am Chem Soc, Vol. 145, Issue 2, Page 851-863, Year 2023 |
Publish date | Jan 18, 2023 |
Authors | Timm O Koller / Ullrich Scheid / Teresa Kösel / Jennifer Herrmann / Daniel Krug / Helena I M Boshoff / Bertrand Beckert / Joanna C Evans / Jan Schlemmer / Becky Sloan / Danielle M Weiner / Laura E Via / Atica Moosa / Thomas R Ioerger / Michael Graf / Boris Zinshteyn / Maha Abdelshahid / Fabian Nguyen / Stefan Arenz / Franziska Gille / Maik Siebke / Tim Seedorf / Oliver Plettenburg / Rachel Green / Anna-Luisa Warnke / Joachim Ullrich / Ralf Warrass / Clifton E Barry / Digby F Warner / Valerie Mizrahi / Andreas Kirschning / Daniel N Wilson / Rolf Müller / |
PubMed Abstract | Resistance of bacterial pathogens against antibiotics is declared by WHO as a major global health threat. As novel antibacterial agents are urgently needed, we re-assessed the broad-spectrum ...Resistance of bacterial pathogens against antibiotics is declared by WHO as a major global health threat. As novel antibacterial agents are urgently needed, we re-assessed the broad-spectrum myxobacterial antibiotic myxovalargin and found it to be extremely potent against . To ensure compound supply for further development, we studied myxovalargin biosynthesis in detail enabling production via fermentation of a native producer. Feeding experiments as well as functional genomics analysis suggested a structural revision, which was eventually corroborated by the development of a concise total synthesis. The ribosome was identified as the molecular target based on resistant mutant sequencing, and a cryo-EM structure revealed that myxovalargin binds within and completely occludes the exit tunnel, consistent with a mode of action to arrest translation during a late stage of translation initiation. These studies open avenues for structure-based scaffold improvement toward development as an antibacterial agent. |
External links | J Am Chem Soc / PubMed:36603206 / PubMed Central |
Methods | EM (single particle) |
Resolution | 2.1 - 3.0 Å |
Structure data | EMDB-14121, PDB-7qq3: EMDB-15905, PDB-8b7y: |
Chemicals | ChemComp-MG: ChemComp-ZN: ChemComp-HOH: ChemComp-FME: ChemComp-SPD: |
Source |
|
Keywords | RIBOSOME / Antibiotic / Myxovalargin A / MyxA / Myxovalargin B / MyxB / fMet-tRNA / P-tRNA |